Hong Chang

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8668063/publications.pdf

Version: 2024-02-01

160 papers	5,345 citations	61984 43 h-index	98798 67 g-index
161 all docs	161 docs citations	161 times ranked	6137 citing authors

#	Article	IF	Citations
1	CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma. Blood, 2005, 105, 2941-2948.	1.4	268
2	p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation. Blood, 2005, 105, 358-360.	1.4	195
3	Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13. Blood, 2009, 114, 522-525.	1.4	178
4	The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant. British Journal of Haematology, 2004, 125, 64-68.	2.5	176
5	Drug resistance in multiple myeloma: latest findings and new concepts on molecular mechanisms. Oncotarget, 2013, 4, 2186-2207.	1.8	145
6	Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leukemia Research, 2004, 28, 1007-1011.	0.8	139
7	The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells. Blood, 2006, 107, 4039-4046.	1.4	139
8	Prognostic relevance of immunophenotyping in 379 patients with acute myeloid leukemia. Leukemia Research, 2004, 28, 43-48.	0.8	116
9	Bone marrow stromal cells protect myeloma cells from bortezomib induced apoptosis by suppressing microRNA-15a expression. Leukemia and Lymphoma, 2011, 52, 1787-1794.	1.3	111
10	Allogeneic Red Blood Cell Transfusion Is an Independent Risk Factor for the Development of Postoperative Bacterial Infection. Vox Sanguinis, 2000, 78, 13-18.	1.5	106
11	miR-137 and miR-197 Induce Apoptosis and Suppress Tumorigenicity by Targeting MCL-1 in Multiple Myeloma. Clinical Cancer Research, 2015, 21, 2399-2411.	7.0	106
12	Multiple myeloma involving central nervous system: high frequency of chromosome 17p13.1 (p53) deletions. British Journal of Haematology, 2004, 127, 280-284.	2.5	103
13	Targeting p53 by small molecules in hematological malignancies. Journal of Hematology and Oncology, 2013, 6, 23.	17.0	99
14	Clinical Outcomes in t(4;14) Multiple Myeloma: A Chemotherapy-Sensitive Disease Characterized by Rapid Relapse and Alkylating Agent Resistance. Journal of Clinical Oncology, 2005, 23, 7069-7073.	1.6	91
15	Multiple myeloma patients with CKS1B gene amplification have a shorter progression-free survival post-autologous stem cell transplantation. British Journal of Haematology, 2006, 135, 486-491.	2.5	85
16	PRIMA-1Met/APR-246 Displays High Antitumor Activity in Multiple Myeloma By Induction of p73 and Noxa. Molecular Cancer Therapeutics, 2013, 12, 2331-2341.	4.1	82
17	Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma. Leukemia Research, 2007, 31, 779-782.	0.8	81
18	Preclinical studies of fibroblast growth factor receptorÂ3 as a therapeutic target in multiple myeloma. British Journal of Haematology, 2004, 124, 595-603.	2.5	79

#	Article	IF	Citations
19	MDM2 antagonist nutlin plus proteasome inhibitor velcade combination displays a synergistic anti-myeloma activity. Cancer Biology and Therapy, 2010, 9, 936-944.	3.4	79
20	Role of CD47 in Hematological Malignancies. Journal of Hematology and Oncology, 2020, 13, 96.	17.0	76
21	Analysis of PTEN deletions and mutations in multiple myeloma. Leukemia Research, 2006, 30, 262-265.	0.8	72
22	1p21 deletions are strongly associated with 1q21 gains and are an independent adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma. Bone Marrow Transplantation, 2010, 45, 117-121.	2.4	71
23	Immunohistochemistry accurately predicts FGFR3 aberrant expression and t(4;14) in multiple myeloma. Blood, 2005, 106, 353-355.	1.4	70
24	Targeting p53 via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma. PLoS ONE, 2012, 7, e30215.	2.5	68
25	Genetic aberrations including chromosome 1 abnormalities and clinical features of plasma cell leukemia. Leukemia Research, 2009, 33, 259-262.	0.8	67
26	Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells. Journal of Hematology and Oncology, 2011, 4, 37.	17.0	67
27	Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS. Leukemia, 2018, 32, 2471-2482.	7.2	63
28	Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma. Leukemia, 2017, 31, 1123-1135.	7.2	61
29	Genetic risk identifies multiple myeloma patients who do not benefit from autologous stem cell transplantation. Bone Marrow Transplantation, 2005, 36, 793-796.	2.4	60
30	Targeting phospho-MARCKS overcomes drug-resistance and induces antitumor activity in preclinical models of multiple myeloma. Leukemia, 2015, 29, 715-726.	7.2	60
31	t(11;14) multiple myeloma: A subtype associated with distinct immunological features, immunophenotypic characteristics but divergent outcome. Leukemia Research, 2013, 37, 1251-1257.	0.8	59
32	Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis. Journal of Hematology and Oncology, 2017, 10, 169.	17.0	55
33	CD7 expression predicts poor disease free survival and post-remission survival in patients with acute myeloid leukemia and normal karyotype. Leukemia Research, 2007, 31, 157-162.	0.8	54
34	Modulating PD-L1 expression in multiple myeloma: an alternative strategy to target the PD-1/PD-L1 pathway. Journal of Hematology and Oncology, 2018, 11, 46.	17.0	53
35	Chromosome 1p21 deletion is a novel prognostic marker in patients with multiple myeloma. British Journal of Haematology, 2007, 139, 51-54.	2.5	52
36	Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma. Cancer Biology and Therapy, 2010, 10, 567-578.	3.4	52

#	Article	IF	Citations
37	Activation of Erk by sonic hedgehog independent of canonical hedgehog signalling. International Journal of Biochemistry and Cell Biology, 2010, 42, 1462-1471.	2.8	52
38	p53 nuclear accumulation is associated with extramedullary progression of multiple myeloma. Leukemia Research, 2009, 33, 1357-1360.	0.8	51
39	Role of epigenetics-microRNA axis in drug resistance of multiple myeloma. Journal of Hematology and Oncology, 2017, 10, 121.	17.0	50
40	The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system. British Journal of Haematology, 2005, 129, 539-541.	2.5	48
41	Prognostic Relevance of 6q Deletion in WaldenstrÃ¶m's Macroglobulinemia: A Multicenter Study. Clinical Lymphoma and Myeloma, 2009, 9, 36-38.	1.4	47
42	Therapyâ€related acute lymphoblastic leukemia is more frequent than previously recognized and has a poor prognosis. Cancer, 2012, 118, 3962-3967.	4.1	47
43	Analysis of IgH translocations, chromosome 13q14 and 17p13.1(p53) deletions by fluorescence in situ hybridization in Waldenstrom's macroglobulinemia: a single center study of 22 cases. Leukemia, 2004, 18, 1160-1162.	7.2	46
44	Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant. Leukemia and Lymphoma, 2006, 47, 43-47.	1.3	45
45	RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic Responses. Molecular Cancer Therapeutics, 2010, 9, 3041-3051.	4.1	45
46	Allogeneic Red Blood Cell Transfusion Is an Independent Risk Factor for the Development of Postoperative Bacterial Infection. Vox Sanguinis, 2000, 78, 13-18.	1.5	45
47	Pharmacological activation of the p53 pathway in haematological malignancies. Journal of Clinical Pathology, 2010, 63, 204-209.	2.0	44
48	Aberrant nuclear p53 protein expression detected by immunohistochemistry is associated with hemizygous P53 deletion and poor survival for multiple myeloma. British Journal of Haematology, 2007, 138, 324-329.	2.5	43
49	EZH2 as a therapeutic target for multiple myeloma and other haematological malignancies. Biomarker Research, 2018, 6, 34.	6.8	41
50	p53 Mutations, c-myc and bcl-2 Rearrangements in Human Non-Hodgkin's Lymphoma Cell Lines. Leukemia and Lymphoma, 1995, 19, 165-171.	1.3	40
51	Impact of cytogenetics in patients with relapsed or refractory multiple myeloma treated with bortezomib: Adverse effect of 1q21 gains. Leukemia Research, 2011, 35, 95-98.	0.8	40
52	Targeting CD47/TNFAIP8 by miR-155 overcomes drug resistance and inhibits tumor growth through induction of phagocytosis and apoptosis in multiple myeloma. Haematologica, 2020, 105, 2813-2823.	3.5	38
53	Role of micro-RNAs in drug resistance of multiple myeloma. Oncotarget, 2016, 7, 60723-60735.	1.8	37
54	Genomic aberrations in plasma cell leukemia shown by interphase fluorescence in situ hybridization. Cancer Genetics and Cytogenetics, 2005, 156, 150-153.	1.0	36

#	Article	IF	Citations
55	The impact of inhibitors on the cost of clotting factor replacement therapy in haemophilia A in Canada. Haemophilia, 1999, 5, 247-252.	2.1	35
56	Frequent monoallelic loss of D13S319 in multiple myeloma patients shown by interphase fluorescence in situ hybridization. Leukemia, 1999, 13, 105-109.	7.2	35
57	Cytoplasmic Expression of Nucleophosmin Accurately Predicts Mutation in the Nucleophosmin Gene in Patients With Acute Myeloid Leukemia and Normal Karyotype. American Journal of Clinical Pathology, 2010, 133, 34-40.	0.7	34
58	Impact of genomic aberrations including chromosome 1 abnormalities on the outcome of patients with relapsed or refractory multiple myeloma treated with lenalidomide and dexamethasone. Leukemia and Lymphoma, 2010, 51, 2084-2091.	1.3	34
59	Significant increase of CKS1B amplification from monoclonal gammopathy of undetermined significance to multiple myeloma and plasma cell leukaemia as demonstrated by interphase fluorescence in situ hybridisation. British Journal of Haematology, 2006, 134, 613-615.	2.5	32
60	Detection of Chromosome 13q Deletions and IgH Translocations in Patients with Multiple Myeloma by FISH: Comparison with Karyotype Analysis. Leukemia and Lymphoma, 2004, 45, 965-969.	1.3	31
61	T-Cell Large Granular Lymphocytic Leukemia of Donor Origin Occurring After Allogeneic Bone Marrow Transplantation for B-Cell Lymphoproliferative Disorders. American Journal of Clinical Pathology, 2005, 123, 196-199.	0.7	31
62	CKS1B nuclear expression is inversely correlated with p27Kip1 expression and is predictive of an adverse survival in patients with multiple myeloma. Haematologica, 2010, 95, 1542-1547.	3.5	31
63	Small molecule MIRA-1 induces in vitro and in vivo anti-myeloma activity and synergizes with current anti-myeloma agents. British Journal of Cancer, 2014, 110, 2224-2231.	6.4	31
64	Micro-RNAs, New performers in multiple myeloma bone marrow microenvironment. Biomarker Research, 2014, 2, 10.	6.8	29
65	miRNA-29a as a tumor suppressor mediates PRIMA-1Met-induced anti-myeloma activity by targeting c-Myc. Oncotarget, 2016, 7, 7149-7160.	1.8	29
66	Analysis of 6q deletion in Waldenstrom macroglobulinemia. European Journal of Haematology, 2007, 79, 244-247.	2.2	28
67	Molecular cytogenetic abnormalities in patients with concurrent chronic lymphocytic leukemia and multiple myeloma shown by interphase fluorescence in situ hybridization: evidence of distinct clonal origin. Cancer Genetics and Cytogenetics, 2004, 148, 44-48.	1.0	27
68	Multiple myeloma acquires resistance to EGFR inhibitor via induction of pentose phosphate pathway. Scientific Reports, 2015, 5, 9925.	3.3	25
69	High IKZF1/3 protein expression is a favorable prognostic factor for survival of relapsed/refractory multiple myeloma patients treated with lenalidomide. Journal of Hematology and Oncology, 2016, 9, 123.	17.0	25
70	The morphological subcategories of acute monocytic leukemia (M5a and M5b) share similar immunophenotypic and cytogenetic features and clinical outcomes. Leukemia Research, 2008, 32, 269-273.	0.8	24
71	Aberrant Nuclear p53 Expression Predicts Hemizygous 17p (TP53)Deletion in Chronic Lymphocytic Leukemia. American Journal of Clinical Pathology, 2010, 133, 70-74.	0.7	24
72	p53 Nuclear Expression Correlates With Hemizygous TP53 Deletion and Predicts an Adverse Outcome for Patients With Relapsed/Refractory Multiple Myeloma Treated With Lenalidomide. American Journal of Clinical Pathology, 2012, 137, 208-212.	0.7	24

#	Article	IF	Citations
73	CD34 expression predicts an adverse outcome in patients with NPM1-positive acute myeloid leukemia. Human Pathology, 2013, 44, 2038-2046.	2.0	24
74	PRIMA-1Met induces apoptosis in WaldenstrÃ¶m's Macroglobulinemia cells independent of p53. Cancer Biology and Therapy, 2015, 16, 799-806.	3.4	22
75	Genomic aberrations and immunohistochemical markers as prognostic indicators in multiple myeloma. Journal of Clinical Pathology, 2008, 61, 832-836.	2.0	21
76	Allogeneic Hematopoietic Cell Transplantation May Alleviate the Negative Prognostic Impact of Monosomal and Complex Karyotypes on Patients with Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2014, 20, 690-695.	2.0	21
77	Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. Journal of Hematology and Oncology, 2010, 3, 13.	17.0	19
78	Genomic aberrations in anaplastic multiple myeloma: High frequency of 1q21(CKS1B) amplifications. Leukemia Research, 2013, 37, 1726-1728.	0.8	19
79	Ectopic expression of BIRC5-targeting miR-101-3p overcomes bone marrow stroma-mediated drug resistance in multiple myeloma cells. BMC Cancer, 2019, 19, 975.	2.6	19
80	Diagnostic evaluation of t(4;14) in multiple myeloma and evidence for clonal evolution. Leukemia, 2007, 21, 2358-2359.	7.2	18
81	Prognostic factors in normal karyotype acute myeloid leukemia in the absence of the FLT3-ITD mutation. Leukemia Research, 2011, 35, 492-498.	0.8	18
82	Constitutive Production of the Interleukins IL-5 and IL-6 by the Lymphoma Cell Line OCI-Ly 17 Derived from a Patient with Malignant Lymphoma and Hypereosinophilia. Leukemia and Lymphoma, 1992, 8, 97-107.	1.3	17
83	c-Maf nuclear oncoprotein is frequently expressed in multiple myeloma. Leukemia, 2007, 21, 1572-1574.	7.2	17
84	Novel Targeting Of Phospho-Marcks Overcomes Drug Resistance and Induces Anti-Tumor Activity In Preclinical Models Of Multiple Myeloma. Blood, 2013, 122, 282-282.	1.4	17
85	Acute leukemia of donor origin arising after stem cell transplantation for acute promyelocytic leukemia. Leukemia Research, 2004, 28, 1107-1111.	0.8	16
86	Cyclin kinase subunit 1B nuclear expression predicts an adverse outcome for patients with relapsed/refractory multiple myeloma treated with bortezomib. Human Pathology, 2012, 43, 858-864.	2.0	16
87	CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavorable acute myeloid leukemia. Leukemia Research, 2013, 37, 122-128.	0.8	16
88	Aberrant expression of T-cell-associated markers CD4 and CD7 on B-cell chronic lymphocytic leukemia. American Journal of Hematology, 2007, 82, 73-76.	4.1	14
89	Adult Precursor T-Lymphoblastic Leukemia/Lymphoma with Myeloid-Associated Antigen Expression Is Associated with a Lower Complete Remission Rate following Induction Chemotherapy. Acta Haematologica, 2008, 120, 5-10.	1.4	14
90	Molecular Characterization of Chronic Lymphocytic Leukemia With Two Distinct Cell Populations. American Journal of Clinical Pathology, 2006, 126, 23-28.	0.7	13

#	Article	IF	Citations
91	Genomic stratification of multiple myeloma treated with novel agents. Leukemia and Lymphoma, 2012, 53, 202-207.	1.3	13
92	Prognostic value of immunophenotyping and gene mutations in elderly patients with acute myeloid leukemia with normal karyotype. Human Pathology, 2013, 44, 55-61.	2.0	13
93	Prognostic relevance of CD123 expression in adult AML with normal karyotype. British Journal of Haematology, 2020, 188, 181-184.	2.5	13
94	Chronic lymphocytic leukemia in the course of chronic myelocytic leukemia: evidence of independent clonal origin as shown by interphase fluorescence in situ hybridization and fluorescence-activated cell sorting. Cancer Genetics and Cytogenetics, 2004, 152, 146-148.	1.0	12
95	Extracorporeal photopheresis in solid organ transplantâ€“associated acute graftâ€versusâ€host disease. Transfusion, 2016, 56, 962-969.	1.6	12
96	MARCKS inhibition cooperates with autophagy antagonists to potentiate the effect of standard therapy against drug-resistant multiple myeloma. Cancer Letters, 2020, 480, 29-38.	7.2	12
97	t(11;14) does not predict long-term survival in myeloma. Leukemia, 2005, 19, 1078-1079.	7.2	11
98	CD33, not early precursor Tâ€cell phenotype, is associated with adverse outcome in adult Tâ€cell acute lymphoblastic leukaemia. British Journal of Haematology, 2016, 172, 823-825.	2.5	11
99	Pathophysiological roles of myristoylated alanine-rich C-kinase substrate (MARCKS) in hematological malignancies. Biomarker Research, 2021, 9, 34.	6.8	10
100	Loss of ALX4 expression in epithelial cells and adjacent stromal cells in breast cancer. Journal of Clinical Pathology, 2009, 62, 908-914.	2.0	9
101	Mammary epithelial-restricted expression of activated c-src rescues the block to mammary gland morphogenesis due to the deletion of the C-terminus of Patched-1. Developmental Biology, 2012, 370, 187-197.	2.0	9
102	T-cell large granular lymphocytic leukemia of donor origin occurring after allogeneic bone marrow transplantation for B-cell lymphoproliferative disorders. American Journal of Clinical Pathology, 2005, 123, 196-9.	0.7	9
103	Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates a superior clinical outcome. Human Pathology, 2020, 104, 117-126.	2.0	8
104	SMAD1 as a biomarker and potential therapeutic target in drug-resistant multiple myeloma. Biomarker Research, 2021, 9, 48.	6.8	8
105	Distinct characteristics and new prognostic scoring system for Chinese patients with WaldenstrÃ¶m macroglobulinemia. Chinese Medical Journal, 2014, 127, 2327-31.	2.3	8
106	Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple Myeloma. Cancers, 2022, 14, 1592.	3.7	8
107	Acute Myeloid Leukemia With Pseudoâ€“ChÃ©diak-Higashi Anomaly Exhibits a Specific Immunophenotype With CD2 Expression. American Journal of Clinical Pathology, 2006, 125, 791-794.	0.7	7
108	CD11b expression correlates with monosomal karyotype and predicts an extremely poor prognosis in cytogenetically unfavourable acute myeloid leukemia. Leukemia Research, 2013, 37, 861.	0.8	6

#	Article	IF	Citations
109	Laboratory practices for manual blood film review: Results of an IQMH patterns of practice survey. International Journal of Laboratory Hematology, 2021, 43, 184-190.	1.3	6
110	NPM1-mutated AML-MRC diagnosed on the basis of history of MDS or MDS/MPN frequently harbours secondary-type mutations and confers inferior outcome compared to AML with mutated NPM1. Leukemia Research, 2022, 118, 106869.	0.8	6
111	Clonality analysis of cell lineages in acute myeloid leukemia with inversion 16. Cancer Genetics and Cytogenetics, 2005, 156, 175-178.	1.0	5
112	Analysis of chromosome 12p deletion in plasma cell dyscrasias. Leukemia Research, 2012, 36, 32-36.	0.8	5
113	Prognostic Effect of Complex Karyotype, Monosomal Karyotype, and Chromosome 17ÂAbnormalities in B-Cell Acute Lymphoblastic Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, 215-219.	0.4	5
114	Expression of <scp>CD</scp>4 is correlated with an unfavorable prognosis in wildâ€type <scp>NPM</scp>1, <scp>FLT</scp>3â€<scp>ITD</scp>â€negative cytogenetically normal adult acute myeloid leukemia. International Journal of Laboratory Hematology, 2017, 39, 429-437.	1.3	5
115	Molecular Mechanisms Mediating Antimyeloma Activity of An MDM2 Antagonist Nutlin.. Blood, 2009, 114, 3841-3841.	1.4	5
116	Molecular Characterization of Chronic Lymphocytic Leukemia With Two Distinct Cell Populations: Evidence for Separate Clonal Origins. American Journal of Clinical Pathology, 2006, 126, 23-28.	0.7	5
117	Dutcher bodies in multiple myeloma are highly associated with translocation t(4;14) and IgA isotype. British Journal of Haematology, 2015, 171, 890-892.	2.5	4
118	Identification of cell lineages involved by t(15;17) in acute promyelocytic leukemia by combined fluorescence activated cell sorting and FISH. Cancer Genetics and Cytogenetics, 2005, 158, 43-48.	1.0	3
119	Genomic Aberrations and Survival of Patients with Light-Chain-Only Multiple Myeloma Undergoing Autologous Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2011, 17, 1790-1795.	2.0	3
120	Synchronous T lymphoblastic lymphoma and myeloid neoplasm with <scp>PDGFRA</scp> rearrangement. International Journal of Laboratory Hematology, 2017, 39, e28-e32.	1.3	3
121	Clinical Proof of Concept Trial of Oral Ciclopirox Olamine in Patients with Relapsed/Refractory Hematologic Malignancy. Blood, 2012, 120, 1372-1372.	1.4	3
122	Prospective audit of cytomegalovirus-negative blood product utilization in haematology/oncology patients. Transfusion Medicine, 1999, 9, 195-198.	1.1	2
123	Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification. Leukemia Research, 2017, 61, 39-43.	0.8	2
124	Combination of FLT3-ITD Allelic Ratio, NPM1 Mutation, and Immunophenotypic Markers to Modulate Outcome Prediction in Patients with Normal Karyotype Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 1995-2000.	2.0	2
125	Coexistence of BCR-ABL1 and RUNX1-RUNX1T1 in a de novo AML. Blood, 2021, 137, 2853-2853.	1.4	2
126	Overexpression of Mir-21-5p Induces Apoptosis and Cell Cycle Arrest By Down-Regulating SKP2 and Overcomes Bortezomib Resistance in Multiple Myeloma. Blood, 2019, 134, 1823-1823.	1.4	2

#	Article	IF	Citations
127	Bortezomib Therapy Response Is Independent of Cytogenetic Abnormalities in Relapsed/Refractory Multiple Myeloma.. Blood, 2006, 108, 5081-5081.	1.4	2
128	Interphase cytogenetic analysis of clonality in peripheral blood cells from a patient with Down syndrome and acute megakaryoblastic leukemia. Cancer Genetics and Cytogenetics, 2004, 148, 141-144.	1.0	1
129	Targeting p53 by small molecule p53 activators in multiple myeloma. Journal of Hematology and Oncology, 2012, 5, .	17.0	1
130	Polyclonal serum IgM level identifies a subgroup of multiple myeloma patients with low-risk clinicobiological features and superior survival. Leukemia Research, 2014, 38, 666-672.	0.8	1
131	Acute myeloid leukemia with mutated <scp>NPM</scp>1 demonstrating multilineage dysplasia and marked thrombocytosis. British Journal of Haematology, 2017, 178, 350-350.	2.5	1
132	Systemic mastocytosis with acute myeloid leukemia occurs from mutually exclusive clones expressing KITD816V and FLT3-ITD. Leukemia, 2021, 35, 282-285.	7.2	1
133	Hemophagocytosis arising during disease progression of chronic myelomonocytic leukemia. International Journal of Laboratory Hematology, 2022, 44, 25-26.	1.3	1
134	Marcks Peptide Inhibitor Displays Synergistic Cytotoxicity with Bortezomib in Drug Resistant Multiple Myeloma Cells but Enhances Autophagic Effect. Blood, 2016, 128, 2061-2061.	1.4	1
135	p53 Deletion Yields High Response Rates but Rapid Progression and Poor Overall Survival in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.. Blood, 2007, 110, 953-953.	1.4	1
136	Small Molecule MIRA-1 Induces p53-Independent Apoptosis in Multiple Myeloma Cells Through Activation of the p38 MAPK Signaling Pathway.. Blood, 2012, 120, 2937-2937.	1.4	1
137	Downregulation of MDM2 Leads to Anti-Proliferative Effects through Activation of p53-Associated Pathway Mediated By Both Dual Inhibitor MX69 and Mir-548c-3p in Multiple Myeloma. Blood, 2019, 134, 4419-4419.	1.4	1
138	Acute Myeloid Leukemia With Pseudo-ChÃ¨diak-Higashi Anomaly Exhibits a Specific Immunophenotype With CD2 Expression. American Journal of Clinical Pathology, 2006, 125, 791-794.	0.7	1
139	Irreversible loss of donor blood leucocyte activation may explain a paucity of transfusionâ€associated graftâ€versusâ€host disease from stored blood. British Journal of Haematology, 2000, 111, 146-156.	2.5	0
140	Mixed phenotype acute leukaemia with predominant myeloid blasts and a small subset of B/myeloid blasts shares the same mutation profile. British Journal of Haematology, 2020, 188, e60-e63.	2.5	0
141	Mixedâ€phenotype acute leukemia with a predominant B/T and a small subset of myeloid lineage expression. EJHaem, 2020, 1, 402-403.	1.0	0
142	Multiple Auer rods in a mixed-phenotype acute leukemia. Blood, 2021, 137, 1702-1702.	1.4	0
143	Coâ€existence of multiple myeloma and perivascular endothelial cell tumor. International Journal of Laboratory Hematology, 2022, 44, 42-43.	1.3	0
144	P53 Gene Deletion Detected by Fluorescence In Situ Hybridization Is an Adverse Prognostic Factor for Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation.. Blood, 2004, 104, 4884-4884.	1.4	0

#	Article	IF	Citations
145	Thalidomide +/â^' Corticosteroids for the Treatment of Multiple Myeloma Patients â‰¥ 70 Years of Age.. Blood, 2004, 104, 4934-4934.	1.4	0
146	Prognostic Relevance of CD56 Expression in Patients with Multiple Myeloma Treated with High-Dose Melphalan-Based Chemotherapy and Autologous Stem Cell Transplant.. Blood, 2005, 106, 5086-5086.	1.4	0
147	Myeloid-Associated Antigen Expression Is an Adverse Factor for Complete Remission Following Induction Chemotherapy of Adult Precursor T-Lymphoblastic Leukemia/Lymphoma (T-ALL).. Blood, 2007, 110, 4228-4228.	1.4	0
148	Treatment of Relapsed and Refractory Multiple Myeloma in Patients with p53 Deletion.. Blood, 2008, 112, 1724-1724.	1.4	0
149	The Impact of Cytogenetics on the Outcomes of Treatment with Lenalidomide Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma.. Blood, 2008, 112, 1731-1731.	1.4	0
150	Small Molecule RITA Induces Apoptosis In Multiple Myeloma Cells through Activation of the p53 Pathway and Induction of ER-Stress response. Blood, 2010, 116, 790-790.	1.4	0
151	Prognostic Relevance of Genomic Aberrations In Light Chain Only Multiple Myeloma. Blood, 2010, 116, 4036-4036.	1.4	0
152	p53-Independent Anti-Myeloma Activity of Prima-1met. Blood, 2011, 118, 1826-1826.	1.4	0
153	MARCKS Confers Resistance to Velcade Through Skp2/p27-Mediated Pathway in Multiple Myeloma. Blood, 2011, 118, 985-985.	1.4	0
154	Targeting p53 Via JNK Pathway: A Novel Role of RITA for Apoptotic Signaling in Multiple Myeloma. Blood, 2011, 118, 1836-1836.	1.4	0
155	Mir-137 and Mir-197 within Chromosome 1p Minimal Deletion Region Regulate Apoptotic Activity in Multiple Myeloma by Targeting MCL 1. Blood, 2012, 120, 322-322.	1.4	0
156	Abnormalities Of FAM46C, AHCYL1, CDC14A and CDKN2C Genes Located At Chromosome 1p Detected By QM-FISH Identifies Deletion Of 1p32.3 Covered CDKN2C Is An Independent Adverse Prognostic Marker In Multiple Myeloma. Blood, 2013, 122, 3145-3145.	1.4	0
157	Small Molecule PRIMA-1 met Sensitizes Waldenstrom Macroglobulinemia Cells To Apoptosis and Displays Synergistic Cytotoxicity With Bortezomib. Blood, 2013, 122, 5143-5143.	1.4	0
158	Tumor Suppressor Microrna-29a/b and Microrna-34a Mediate Small Molecule PRIMA-1Met-Induced Aoptosis In Multiple Myeloma Cells By Targeting c-Myc. Blood, 2013, 122, 1919-1919.	1.4	0
159	IKZF1/3 Protein Expressions Are Associated with a Better Survival in Relapsed/Refractory Multiple Myeloma Patients Treated with Lenalidomide. Blood, 2016, 128, 4506-4506.	1.4	0
160	Megakaryocytic emperipolesis in a therapyâ€related acuteâ€mixed phenotypic leukemia. International Journal of Laboratory Hematology, 2022, 44, 694-695.	1.3	0